Effects of Enamel Matrix Derivative in the Treatment of Peri-implant Mucositis
Effects of Enamel Matrix Derivative in the Non-surgical Mechanical Debridement Treatment of Peri-implant Mucositis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ct
-
Catania, Ct, Italy, 95124
- Policlinico G. Rodolico
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age ≥18 years old;
- implants with smooth necks supporting cemented or screw-retained single-unit crowns with at least one BOP-positive site (Berglundh et al., 2018),
- implants placed in both maxilla and mandible
- patients with gingivitis or treated periodontitis with the absence of residual PD ≥5 mm
- presence at least of 2 mm of keratinized mucosa (KT) at implant sites
Exclusion Criteria:
- presence of systemic diseases;
- pregnancy or lactating;
- use of inflammatory drugs or antibiotics within 3 months prior to study recruitment;
- implants with modified (i.e., micro-rough) necks;
- interproximal open contacts between implant restoration and adjacent teeth; peri-implantitis (Berglundh et al., 2018)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Comparator: non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo gel
Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with placebo
|
Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
|
|
Active Comparator: non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD
Patients received a one-session of non-surgical sub-marginal peri-implant instrumentation (NSPI) with EMD
|
Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bleeding on probing (BOP) changes
Time Frame: 6-months
|
The number of implants presenting with complete absence of BOP or implants with limited extent of BOP (≤1 spot/implant-the presence of a single spot)
|
6-months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Probing pocket depth (PPD) changes
Time Frame: 6-months
|
Changes in PPD
|
6-months
|
|
Plaque at implant sites according to modified gingival index (mGI) changes score
Time Frame: 6-months
|
Changes in mGI 0-4 score
|
6-months
|
|
Plaque at implant sites according to modified plaque index (mPlI) changes score
Time Frame: 6-months
|
Changes in mPlI 0-4 score
|
6-months
|
|
Full mouth plaque score (FMPS) % changes
Time Frame: 6-months
|
Full mouth plaque score (FMPS) % changes
|
6-months
|
|
Full mouth bleeding score (FMBS) % changes
Time Frame: 6-months
|
Changes in FMBS
|
6-months
|
|
Patient-Reported Outcome Measures (PROMs)
Time Frame: 6-months
|
Patient-Reported Outcome Measures (PROMs) Were evaluated PROMs such as the number of abscesses, systemic complications, gingival recession, excessive bleeding, allergic effects, systemic impacts and related drug side effects
|
6-months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gaetano Isola, DDS, University of Catania
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-3306
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.